Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferinject in congestive heart failure and iron deficiency
NCT01837082Phase 3Terminated
- Sponsor
- Ulm University
- Start
- Apr 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ferric carboxymaltose in heart failure (HF) and iron deficiency anemia (IDA) (2 arms), sponsored by Ulm University. Primary endpoint: Left-ventricular ejection fraction at 12 weeks. Started Apr 2013; status: terminated.
02
Drugs
ferric carboxymaltose
03
Conditions
heart failure (HF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT01837082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01837082.